Search

Your search keyword '"Paolilo, Renata Barbosa"' showing total 21 results
Start Over Author "Paolilo, Renata Barbosa"
21 results on '"Paolilo, Renata Barbosa"'

3. Brazilian consensus recommendations on the diagnosis and treatment of autoimmune encephalitis in the adult and pediatric populations

Author

Dutra, Lívia Almeida, Silva, Pedro Victor de Castro, Ferreira, João Henrique Fregadolli, Marques, Alexandre Coelho, Toso, Fabio Fieni, Vasconcelos, Claudia Cristina Ferreira, Brum, Doralina Guimarães, Pereira, Samira Luisa dos Apóstolos, Adoni, Tarso, Rocha, Leticia Januzi de Almeida, Sampaio, Leticia Pereira de Brito, Sousa, Nise Alessandra de Carvalho, Paolilo, Renata Barbosa, Pizzol, Angélica Dal, Costa, Bruna Klein da, Disserol, Caio César Diniz, Pupe, Camila, Valle, Daniel Almeida do, Diniz, Denise Sisterolli, Abrantes, Fabiano Ferreira de, Schmidt, Felipe da Rocha, Cendes, Fernando, Oliveira, Francisco Tomaz Meneses de, Martins, Gabriela Joca, Silva, Guilherme Diogo, Lin, Katia, Pinto, Lécio Figueira, Santos, Mara Lúcia Schimtz Ferreira, Gonçalves, Marcus Vinícius Magno, Krueger, Mariana Braatz, Haziot, Michel Elyas Jung, Barsottini, Orlando Graziani Povoas, Nascimento, Osvaldo José Moreira do, Nóbrega, Paulo Ribeiro, Proveti, Priscilla Mara, Castilhos, Raphael Machado do, Daccach, Vanessa, and Glehn, Felipe von

Published
2024
Full Text
View/download PDF

4. Post-vaccination Guillain-Barre syndrome: a case report

Author

Barros, Nicholas dos Santos, additional, da Paz, José Albino, additional, Paolilo, Renata Barbosa, additional, Coimbra, Clarice Semião, additional, de Almeida, Roberta Diniz, additional, Dantas, Rafaela Fernandes, additional, Leão, Ana Cristina Azevedo, additional, de Mendonça, Renata Silva, additional, and Hayashi, Daniel Shoji, additional

Published
2023
Full Text
View/download PDF

5. Use of plasmapheresis in acquired demyelinating syndromes

Author

de Almeida, Roberta Diniz, additional, da Paz, José Albino, additional, Paolilo, Renata Barbosa, additional, Coimbra, Clarice Semião, additional, Dantas, Rafaela Fernandes, additional, Barros, Nicholas dos Santos, additional, Leão, Ana Cristina Azevedo, additional, de Mendonça, Renata Silva, additional, and Cruz, Cristiani Rocha Lima, additional

Published
2023
Full Text
View/download PDF

6. Tourettism secondary to multiple sclerosis

Author

de Almeida, Roberta Diniz, additional, da Paz, José Albino, additional, Paolilo, Renata Barbosa, additional, Coimbra, Clarice Semião, additional, Dantas, Rafaela Fernandes, additional, Barros, Nicholas dos Santos, additional, Leão, Ana Cristina Azevedo, additional, Hayashi, Daniel Shoji, additional, and Brito, Joemir Jabson da Conceição, additional

Published
2023
Full Text
View/download PDF

9. Reducing infection risk in multiple sclerosis and neuromyelitis optica spectrum disorders: a Brazilian reference center's approach

Author

Gomes, Ana Beatriz Ayroza Galvão Ribeiro, additional, Feo, Lucas Bueno, additional, Silva, Guilherme Diogo, additional, Disserol, Caio César Diniz, additional, Paolilo, Renata Barbosa, additional, Lara, Amanda Nazareth, additional, Tonácio, Adriana Coracini, additional, Mendes, Maria Fernanda, additional, Pereira, Samira Luísa Apóstolos, additional, and Callegaro, Dagoberto, additional

Published
2022
Full Text
View/download PDF

10. Recommendations by the Scientific Department of Neuroimmunology of the Brazilian Academy of Neurology (DCNI/ABN) and the Brazilian Committee for Treatment and Research in Multiple Sclerosis and Neuroimmunological Diseases (BCTRIMS) on vaccination in general and specifically against SARS-CoV-2 for patients with demyelinating diseases of the central nervous system

Author

Becker, Jefferson, Ferreira, Lis Campos, Damasceno, Alfredo, Bichuetti, Denis Bernardi, Christo, Paulo Pereira, Callegaro, Dagoberto, Peixoto, Marco Aurélio Lana, Sousa, Nise Alessandra De Carvalho, Almeida, Sérgio Monteiro De, Adoni, Tarso, Santiago-Amaral, Juliana, Junqueira, Thiago, Pereira, Samira Luisa Apóstolos, Gomes, Ana Beatriz Ayroza Galvão Ribeiro, Pitombeira, Milena, Paolilo, Renata Barbosa, Grzesiuk, Anderson Kuntz, Piccolo, Ana Claudia, D´Almeida, José Arthur Costa, Gomes Neto, Antonio Pereira, Oliveira, Augusto Cesar Penalva De, Oliveira, Bianca Santos De, Tauil, Carlos Bernardo, Vasconcelos, Claudia Ferreira, Kaimen-Maciel, Damacio, Varela, Daniel, Diniz, Denise Sisterolli, Oliveira, Enedina Maria Lobato De, Malfetano, Fabiola Rachid, Borges, Fernando Elias, Figueira, Fernando Faria Andrade, Gondim, Francisco De Assis Aquino, Passos, Giordani Rodrigues Dos, Silva, Guilherme Diogo, Olival, Guilherme Sciascia Do, Santos, Gutemberg Augusto Cruz Dos, Ruocco, Heloisa Helena, Sato, Henry Koiti, Soares Neto, Herval Ribeiro, Cortoni Calia, Leandro, Gonçalves, Marcus Vinícius Magno, Vecino, Maria Cecilia Aragón De, Pimentel, Maria Lucia Vellutini, Ribeiro, Marlise De Castro, Boaventura, Mateus, Parolin, Mônica Koncke Fiuza, Melo, Renata Brant De Souza, Lázaro, Robson, Thomaz, Rodrigo Barbosa, Kleinpaul, Rodrigo, Dias, Ronaldo Maciel, Gomes, Sidney, Lucatto, Simone Abrante, Alves-Leon, Soniza Vieira, Fukuda, Thiago, Ribeiro, Taysa Alexandrino Gonsalves Jubé, Winckler, Thereza Cristina D’ávila, Fragoso, Yara Dadalti, Nascimento, Osvaldo José Moreira Do, Ferreira, Maria Lucia Brito, Mendes, Maria Fernanda, Brum, Doralina Guimarães, Glehn, Felipe Von, Pontifícia Universidade Católica Do Rio Grande Do Sul, Universidade Federal de Sergipe (UFS), Universidade Tiradentes, Universidade Estadual de Campinas (UNICAMP), Universidade Federal de São Paulo (UNIFESP), Universidade Federal de Minas Gerais (UFMG), Universidade de São Paulo (USP), Universidade Federal Do Amazonas, Universidade Federal do Paraná (UFPR), Hospital Sírio Libanês, Escola Bahiana de Medicina e Saúde Pública, Hospital Geral de Fortaleza, Clínica Nossa Senhora das Graças, Hospital Santa Marcelina, Santa Casa, Instituto de Infectologia Emílio Ribas, Fundação Centro Integrado de Apoio Ao Portador de Deficiência, Secretaria de Estado da Saúde, Universidade Federal do Rio de Janeiro (UFRJ), Hospital de Clínicas de Passo Fundo, Universidade Federal de Goiás (UFG), Universidade Estácio de Sá, Hospital São Francisco Na Providência de Deus, Universidade Federal Do Ceará, Associação Brasileira de Esclerose Múltipla, Universidade Federal Fluminense (UFF), Pontifícia Universidade Católica, Instituto de Neurologia de Curitiba, IAMSPE, Private Service, Universidade da Região de Joinville, Hospital Moinhos de Vento, Universidade Federal Ciências da Saúde de Porto Alegre, Faculdade de Medicina de Jundiaí, Hospital Israelita Albert Einstein, Hospital de Base Do Distrito Federal, Hospital Beneficiência Portuguesa, Hospital Regional de Vilhena, Universidade Federal Do Estado Do Rio de Janeiro, Hospital Universitário Prof. Edgar Santos, Universidade Metropolitana de Santos, Hospital da Restauração, Universidade Estadual Paulista (UNESP), and Universidade de Brasília (UnB)

Subjects
Vacinação, Multiple Sclerosis, Doenças Autoimunes Desmielinizantes do Sistema Nervoso Central, Neuromielite Óptica, SARS-CoV-2, Esclerose Múltipla, Vaccination, Neuromyelitis Optica, COVID-19, Demyelinating Autoimmune Diseases, CNS
Abstract

Made available in DSpace on 2022-04-29T08:46:09Z (GMT). No. of bitstreams: 0 Previous issue date: 2021-11-01 The Scientific Department of Neuroimmunology of the Brazilian Academy of Neurology (DCNI/ABN) and Brazilian Committee for Treatment and Research in Multiple Sclerosis and Neuroimmunological Diseases (BCTRIMS) provide recommendations in this document for vaccination of the population with demyelinating diseases of the central nervous system (CNS) against infections in general and against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19. We emphasize the seriousness of the current situation in view of the spread of COVID-19 in our country. Therefore, reference guides on vaccination for clinicians, patients, and public health authorities are particularly important to prevent some infectious diseases. The DCNI/ABN and BCTRIMS recommend that patients with CNS demyelinating diseases (e.g., MS and NMOSD) be continually monitored for updates to their vaccination schedule, especially at the beginning or before a change in treatment with a disease modifying drug (DMD). It is also important to note that vaccines are safe, and physicians should encourage their use in all patients. Clearly, special care should be taken when live attenuated viruses are involved. Finally, it is important for physicians to verify which DMD the patient is receiving and when the last dose was taken, as each drug may affect the induction of immune response differently. Pontifícia Universidade Católica Do Rio Grande Do Sul, RS Universidade Federal de Sergipe, SE Universidade Tiradentes, SE Universidade de Campinas Faculdade de Ciências Médicas, SP Universidade Federal de São Paulo Escola Paulista de Medicina, SP Universidade Federal de Minas Gerais, MG Universidade de São Paulo Faculdade de Medicina Hospital das Clínicas, SP Universidade Federal Do Amazonas, AM Universidade Federal Do Paraná, PR Hospital Sírio Libanês, SP Escola Bahiana de Medicina e Saúde Pública, BA Hospital Geral de Fortaleza, CE Clínica Nossa Senhora das Graças, MS Hospital Santa Marcelina, SP Santa Casa, MG Instituto de Infectologia Emílio Ribas, SP Fundação Centro Integrado de Apoio Ao Portador de Deficiência, PB Secretaria de Estado da Saúde, DF Universidade Federal Do Rio de Janeiro, RJ Santa Casa, PR Hospital de Clínicas de Passo Fundo, RS Universidade Federal de Goiás, GO Universidade Estácio de Sá, RJ Hospital São Francisco Na Providência de Deus, RJ Universidade Federal Do Ceará, CE Associação Brasileira de Esclerose Múltipla, SP Santa Casa, SP Universidade Federal Fluminense, RJ Pontifícia Universidade Católica, SP Instituto de Neurologia de Curitiba, PR IAMSPE, SP Private Service, SP Universidade da Região de Joinville, SC Hospital Moinhos de Vento, RS Santa Casa, RJ Universidade Federal Ciências da Saúde de Porto Alegre, RS Faculdade de Medicina de Jundiaí, SP Hospital Israelita Albert Einstein, SP Hospital de Base Do Distrito Federal, DF Hospital Beneficiência Portuguesa, SP Hospital Regional de Vilhena, RO Universidade Federal Do Estado Do Rio de Janeiro, RJ Hospital Universitário Prof. Edgar Santos, BA Universidade Metropolitana de Santos, SP Hospital da Restauração, PE Universidade Estadual Paulista Faculdade de Medicina de Botucatu, SP Universidade de Brasília Faculdade de Medicina, DF Universidade Estadual Paulista Faculdade de Medicina de Botucatu, SP

Published
2021

11. Recommendations by the Scientific Department of Neuroimmunology of the Brazilian Academy of Neurology (DCNI/ABN) and the Brazilian Committee for Treatment and Research in Multiple Sclerosis and Neuroimmunological Diseases (BCTRIMS) on vaccination in general and specifically against SARS-CoV-2 for patients with demyelinating diseases of the central nervous system

Author

Becker, Jefferson, primary, Ferreira, Lis Campos, additional, Damasceno, Alfredo, additional, Bichuetti, Denis Bernardi, additional, Christo, Paulo Pereira, additional, Callegaro, Dagoberto, additional, Peixoto, Marco Aurélio Lana, additional, Sousa, Nise Alessandra De Carvalho, additional, Almeida, Sérgio Monteiro De, additional, Adoni, Tarso, additional, Santiago-Amaral, Juliana, additional, Junqueira, Thiago, additional, Pereira, Samira Luisa Apóstolos, additional, Gomes, Ana Beatriz Ayroza Galvão Ribeiro, additional, Pitombeira, Milena, additional, Paolilo, Renata Barbosa, additional, Grzesiuk, Anderson Kuntz, additional, Piccolo, Ana Claudia, additional, D´Almeida, José Arthur Costa, additional, Gomes Neto, Antonio Pereira, additional, Oliveira, Augusto Cesar Penalva De, additional, Oliveira, Bianca Santos De, additional, Tauil, Carlos Bernardo, additional, Vasconcelos, Claudia Ferreira, additional, Kaimen-Maciel, Damacio, additional, Varela, Daniel, additional, Diniz, Denise Sisterolli, additional, Oliveira, Enedina Maria Lobato De, additional, Malfetano, Fabiola Rachid, additional, Borges, Fernando Elias, additional, Figueira, Fernando Faria Andrade, additional, Gondim, Francisco De Assis Aquino, additional, Passos, Giordani Rodrigues Dos, additional, Silva, Guilherme Diogo, additional, Olival, Guilherme Sciascia Do, additional, Santos, Gutemberg Augusto Cruz Dos, additional, Ruocco, Heloisa Helena, additional, Sato, Henry Koiti, additional, Soares Neto, Herval Ribeiro, additional, Cortoni Calia, Leandro, additional, Gonçalves, Marcus Vinícius Magno, additional, Vecino, Maria Cecilia Aragón De, additional, Pimentel, Maria Lucia Vellutini, additional, Ribeiro, Marlise De Castro, additional, Boaventura, Mateus, additional, Parolin, Mônica Koncke Fiuza, additional, Melo, Renata Brant De Souza, additional, Lázaro, Robson, additional, Thomaz, Rodrigo Barbosa, additional, Kleinpaul, Rodrigo, additional, Dias, Ronaldo Maciel, additional, Gomes, Sidney, additional, Lucatto, Simone Abrante, additional, Alves-Leon, Soniza Vieira, additional, Fukuda, Thiago, additional, Ribeiro, Taysa Alexandrino Gonsalves Jubé, additional, Winckler, Thereza Cristina D’ávila, additional, Fragoso, Yara Dadalti, additional, Nascimento, Osvaldo José Moreira Do, additional, Ferreira, Maria Lucia Brito, additional, Mendes, Maria Fernanda, additional, Brum, Doralina Guimarães, additional, and Glehn, Felipe Von, additional

Published
2021
Full Text
View/download PDF

14. Acute disseminated encephalomyelitis:Current perspectives

Author

Paolilo, Renata Barbosa, Deiva, Kumaran, Neuteboom, Rinze, Rostásy, Kevin, Lim, Ming, Paolilo, Renata Barbosa, Deiva, Kumaran, Neuteboom, Rinze, Rostásy, Kevin, and Lim, Ming

Abstract

Acute disseminated encephalomyelitis (ADEM) is an immune-mediated central nervous system (CNS) disorder, characterized by polyfocal symptoms, encephalopathy and typical magnetic resonance imaging (MRI) findings, that especially affects young children. Advances in understanding CNS neuroimmune disorders as well as the association of myelin oligodendrocyte glycoprotein antibody (MOG-Ab) with both monophasic and recurrent forms of ADEM have led to new insights into its definition, management and outcome. In this review, we aim to provide an update based on current epidemiologic, clinical, radiological and immunopathological aspects and clinical outcome of ADEM.

Published
2020

15. Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders.

Author

Abboud, Hesham, Salazar-Camelo, Andrea, George, Naveen, Planchon, Sarah M., Matiello, Marcelo, Mealy, Maureen A., Goodman, Andrew, On-behalf of the Guthy-Jackson Foundation NMO International Clinical Consortium, Alroughani, Raed, Altintas, Ayse, Apiwattanakul, Metha, Asgari, Nasrin, Paolilo, Renata Barbosa, Bennett, Jeffrey, Bichuetti, Denis Bernardi, Blaschke, Terrence F., Boyko, Alexey, Broadley, Simon, Carnero Contentti, Edgar, and Cohen, Jeffrey A.

Subjects
NEUROMYELITIS optica, SPINAL cord, MESENCHYMAL stem cells, NEURALGIA, SLEEP disorders, STEM cell transplantation
Abstract

Neuromyelitis optica spectrum disorders (NMOSD) are a group of autoimmune inflammatory conditions that primarily target the optic nerves, spinal cord, brainstem, and occasionally the cerebrum. NMOSD is characterized by recurrent attacks of visual, motor, and/or sensory dysfunction that often result in severe neurological deficits. In recent years, there has been a significant progress in relapse treatment and prevention but the residual disability per attack remains high. Although symptomatic and restorative research has been limited in NMOSD, some therapeutic approaches can be inferred from published case series and evidence from multiple sclerosis literature. In this review, we will discuss established and emerging therapeutic options for symptomatic treatment and restoration of function in NMOSD. We highlight NMOSD-specific considerations and identify potential areas for future research. The review covers pharmacologic, non-pharmacologic, and neuromodulatory approaches to neuropathic pain, tonic spasms, muscle tone abnormalities, sphincter dysfunction, motor and visual impairment, fatigue, sleep disorders, and neuropsychological symptoms. In addition, we briefly discuss remyelinating agents and mesenchymal stem cell transplantation in NMOSD. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

17. Treatment and outcome of aquaporin-4 antibody–positive NMOSD

Author

Paolilo, Renata Barbosa, primary, Hacohen, Yael, additional, Yazbeck, Elise, additional, Armangue, Thais, additional, Bruijstens, Arlette, additional, Lechner, Christian, additional, Apostolos-Pereira, Samira Luisa, additional, Martynenko, Yana, additional, Breu, Markus, additional, de Medeiros Rimkus, Carolina, additional, Wassmer, Evangeline, additional, Baumann, Matthias, additional, Papetti, Laura, additional, Capobianco, Marco, additional, Kornek, Barbara, additional, Rostásy, Kevin, additional, da Paz, José Albino, additional, Ciccarelli, Olga, additional, Lim, Ming, additional, Saiz, Albert, additional, Neuteboom, Rinze, additional, Marignier, Romain, additional, Hemingway, Cheryl, additional, Sato, Douglas Kazutoshi, additional, and Deiva, Kumaran, additional

Published
2020
Full Text
View/download PDF

20. COVID-19 in children and adolescents with neuroimmunological disorders.

Author

Pessoa IL, Paolilo RB, and da Paz JA

Subjects
Humans, Child, Adolescent, COVID-19
Abstract

Competing Interests: Conflicts of interest The authors declare no conflicts of interest. Ingrid Lacerda Pessoa: Reports no disclosure. Renata Barbosa Paolilo: Reports grants from Roche and Merck and speaker honoraria from Novartis, outside the submitted work. José Albino da Paz: reports no disclosure.

Published
2022
Full Text
View/download PDF

21. Treatment and outcome of aquaporin-4 antibody-positive NMOSD: A multinational pediatric study.

Author

Paolilo RB, Hacohen Y, Yazbeck E, Armangue T, Bruijstens A, Lechner C, Apostolos-Pereira SL, Martynenko Y, Breu M, de Medeiros Rimkus C, Wassmer E, Baumann M, Papetti L, Capobianco M, Kornek B, Rostásy K, da Paz JA, Ciccarelli O, Lim M, Saiz A, Neuteboom R, Marignier R, Hemingway C, Sato DK, and Deiva K

Subjects
Adolescent, Autoantibodies blood, Brazil, Child, Child, Preschool, Europe, Female, Humans, Infant, Male, Neuromyelitis Optica immunology, Recurrence, Retrospective Studies, Aquaporin 4 immunology, Disease Progression, Immunologic Factors pharmacology, Neuromyelitis Optica drug therapy, Neuromyelitis Optica physiopathology, Outcome Assessment, Health Care
Abstract

Objective: To describe the clinical phenotypes, treatment response, and outcome of children with antibodies against aquaporin-4 (AQP4-Ab) neuromyelitis optica spectrum disorder (NMOSD)., Methods: Retrospective, multicenter, and multinational study of patients with AQP4-Ab NMOSD aged <18 years at disease onset from a center in Brazil and 13 European centers. Data on demographics, clinical findings, and laboratory results were analyzed; calculation of annualized relapse rates (ARRs) pre- and on-treatment with disease-modifying therapies (DMTs) and of ORs for predictors of poor outcome was performed., Results: A total of 67 children were identified. At last follow-up (median 4 years, interquartile range 2-10 years), 37/67(57.8%) were found to have permanent disability. A more severe disease course was seen in the non-White ethnicity with both a shorter time to first relapse ( p = 0.049) and a worse Expanded Disability Status Scale score at last follow-up ( p = 0.008). The median ARR on treatment was 0.18 on azathioprine (n = 39, range 0-4), 0 on mycophenolate mofetil (n = 18, range 0-3), and 0 on rituximab (n = 29, range 0-2). No patient treated with rituximab as first-line therapy relapsed. Optic neuritis at onset was associated with a poor visual outcome below 20/200 (OR 8.669, 95% CI 1.764-42.616, p = 0.008), and a younger age at onset was associated with cognitive impairment (OR 0.786, 95% CI 0.644-0.959, p = 0.018)., Conclusions: AQP4-Ab NMOSD in children is an aggressive disease with permanent disabilities observed in over half the cohort. All DMTs were associated with a reduction of ARR. First-line rituximab prevented further clinical relapses. International consensus on treatment protocols for children is required to reduce heterogeneity of treatment regimens used worldwide., Classification of Evidence: This study provides Class IV evidence that for children with AQP4-Ab NMOSD, all DMTs, particularly first-line rituximab, reduced the ARR and prevented further clinical relapses., (Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results